Chemical development of the vasopressin receptor 2 antagonist SR-121463

被引:19
作者
Hermecz, I
Sánta-Csutor, A
Gönczi, C
Héja, G
Csikós, É
Simon, K
Smelkó-Esek, A
Podányi, B
机构
[1] Chinoin Chem & Pharmaceut Works Ltd, Preclin Dev Lab, H-1045 Budapest, Hungary
[2] Chinoin Chem & Pharmaceut Works Ltd, Synthet Dev Lab, H-1045 Budapest, Hungary
[3] Chinoin Chem & Pharmaceut Works Ltd, Preclin Analyt Dev Labs, H-1045 Budapest, Hungary
关键词
D O I
10.1351/pac200173091401
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A facile convergent total synthesis of the selective, potent, and orally active V-2 nonpeptide antagonist, SR-121463, was developed by modification of the discovery route. One of the late intermediates, the sulfonyl chloride 1, was synthesized from 3-hydroxybenzoic acid (19) by regioselective sulfonation, O-methylation and amidation in four steps. Another late intermediate, indolin-2-one 2, was prepared from p-phenetidine (8) through the indolin-2-one 16, where the cyclohexanone moiety of 27 was introduced into the active 3-methylene group of 16 by sequential transformation using methyl acrylate and KOtBu. After formation of the cyclic ketal moiety of 13, its ring-opening was achieved by using NaBH4 in the presence of CCl3COOH. The morpholino group in 2 was introduced in accordance with the discovery approach, starting from the 2-hydroxyethoxy derivative 14 through the tosyloxy derivative 15 with morpholine in a one-pot reaction. In this way, the indolin-2-one 2 was synthesized from 8 in six steps. Finally, acylation of the indolin-2-one 2 was achieved with the sulfonyl chloride I in the presence of KOtBu in dimethyl sulfoxide (DMSO) at room temperature. This synthetic route proved to be applicable for the large-scale synthesis of SR-121463.
引用
收藏
页码:1401 / 1409
页数:9
相关论文
共 37 条
[1]   5-fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985):: An orally active arginine vasopressin antagonist with selectivity for V2 receptors [J].
Albright, JD ;
Reich, MF ;
Delos Santos, EG ;
Dusza, JP ;
Sum, FW ;
Venkatesan, AM ;
Coupet, J ;
Chan, PS ;
Ru, X ;
Mazandarani, H ;
Bailey, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (14) :2442-2444
[2]  
ANTONI FA, 1986, MOL PHARMACOL, V30, P171
[3]   Molecular pharmacology of AVP and OT receptors and therapeutic potential [J].
Barberis, C ;
Morin, D ;
Durroux, T ;
Mouillac, B ;
Guillon, G ;
Seyer, R ;
Hibert, M ;
Tribollet, E ;
Manning, M .
DRUG NEWS & PERSPECTIVES, 1999, 12 (05) :279-292
[4]  
Bergmann E.D., 1959, ORG REACTIONS, V10, P179
[5]   MOLECULAR-CLONING OF THE RECEPTOR FOR HUMAN ANTIDIURETIC-HORMONE [J].
BIRNBAUMER, M ;
SEIBOLD, A ;
GILBERT, S ;
ISHIDO, M ;
BARBERIS, C ;
ANTARAMIAN, A ;
BRABET, P ;
ROSENTHAL, W .
NATURE, 1992, 357 (6376) :333-335
[6]   VASCULAR-RESPONSES TO VASOPRESSIN ANTAGONISTS IN MAN AND RAT [J].
BURRELL, LM ;
PHILLIPS, PA ;
ROLLS, KA ;
BUXTON, BF ;
JOHNSTON, CI ;
LIU, JJ .
CLINICAL SCIENCE, 1994, 87 (04) :389-395
[7]   Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors [J].
Chan, WY ;
Wo, NC ;
Stoev, S ;
Cheng, LL ;
Manning, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (04) :803-811
[8]  
Chang BW, 1998, CLIN PLAST SURG, V25, P223
[9]  
COCKERILL AF, 1977, CHEM FUNCTIONAL 1 A, P158
[10]   CLONING AND CHARACTERIZATION OF THE HUMAN V3 PITUITARY VASOPRESSIN RECEPTOR [J].
DEKEYZER, Y ;
AUZAN, C ;
LENNE, F ;
BELDJORD, C ;
THIBONNIER, M ;
BERTAGNA, X ;
CLAUSER, E .
FEBS LETTERS, 1994, 356 (2-3) :215-220